These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35970525)

  • 61. Antimelanoma Differentiation-Associated Gene 5 Antibody-Positive Interstitial Lung Disease After Vaccination With COVID-19 mRNA Vaccines.
    Kitajima T; Funauchi A; Nakajima T; Marumo S; Imura Y; Fukui M
    J Rheumatol; 2022 Oct; 49(10):1158-1162. PubMed ID: 35705246
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Interstitial lung disease with anti-melanoma differentiation-associated gene 5 antibody after allogeneic hematopoietic stem cell transplantation.
    Tamaki M; Matsumi S; Nakasone H; Nakamura Y; Kawamura M; Kawamura S; Takeshita J; Yoshino N; Misaki Y; Yoshimura K; Gomyo A; Tanihara A; Okada Y; Kusuda M; Kameda K; Kimura SI; Kako S; Kanda Y
    Bone Marrow Transplant; 2022 Sep; 57(9):1382-1388. PubMed ID: 35661835
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Successful rituximab treatment for severe rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive juvenile dermatomyositis: a case report and literature review.
    Nishi K; Ogura M; Tamai N; Gima M; Ide K; Koinuma G; Kamei K; Ito S
    Pediatr Rheumatol Online J; 2022 Aug; 20(1):60. PubMed ID: 35927666
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Myocardial involvement is not rare in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis/clinically amyopathic dermatomyositis: a retrospective study.
    Zhou S; Lai J; Wu C; Liu Y; Liu Y; Zhao J; Xu D; Tian X; Li M; Zhao Y; Wang Y; Wang Q; Zeng X
    Front Immunol; 2022; 13():928861. PubMed ID: 35983058
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease.
    Yoshida N; Okamoto M; Kaieda S; Fujimoto K; Ebata T; Tajiri M; Nakamura M; Tominaga M; Wakasugi D; Kawayama T; Kuwana M; Mimori T; Ida H; Hoshino T
    Respir Investig; 2017 Jan; 55(1):24-32. PubMed ID: 28012490
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM.
    Koga T; Fujikawa K; Horai Y; Okada A; Kawashiri SY; Iwamoto N; Suzuki T; Nakashima Y; Tamai M; Arima K; Yamasaki S; Nakamura H; Origuchi T; Hamaguchi Y; Fujimoto M; Ishimatsu Y; Mukae H; Kuwana M; Kohno S; Eguchi K; Aoyagi K; Kawakami A
    Rheumatology (Oxford); 2012 Jul; 51(7):1278-84. PubMed ID: 22378718
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Clinical significance of radiological patterns of HRCT and their association with macrophage activation in dermatomyositis.
    Zuo Y; Ye L; Liu M; Li S; Liu W; Chen F; Lu X; Gordon P; Wang G; Shu X
    Rheumatology (Oxford); 2020 Oct; 59(10):2829-2837. PubMed ID: 32065646
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Clinical features of patients with anti-melanoma differentiation-associated gene-5 antibody-positive dermatomyositis complicated by spontaneous pneumomediastinum.
    Yamaguchi K; Yamaguchi A; Itai M; Kashiwagi C; Takehara K; Aoki S; Sawada Y; Taguchi K; Umetsu K; Oshima K; Uchida M; Takemura M; Hara K; Motegi SI; Muro Y; Nakasatomi M; Sakairi T; Hiromura K; Kurabayashi M; Maeno T
    Clin Rheumatol; 2019 Dec; 38(12):3443-3450. PubMed ID: 31420814
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Anti-Ro52 antibodies are associated with the prognosis of adult idiopathic inflammatory myopathy-associated interstitial lung disease.
    Gui X; Shenyun S; Ding H; Wang R; Tong J; Yu M; Zhao T; Ma M; Ding J; Xin X; Qiu Y; Qiu X; Zhang Y; Cao M; Huang M; Cao M; Dai J; Cai H; Xiao Y
    Rheumatology (Oxford); 2022 Nov; 61(11):4570-4578. PubMed ID: 35148366
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Palmar erythema and palmar papules as predictors for dermatomyositis-related acute/subacute interstitial lung disease: a retrospective study.
    Lu J; Liu C; Zhou X; Tang J; Liu S; Tang M; Li M; Zhu L
    Rheumatology (Oxford); 2021 Dec; 61(1):413-421. PubMed ID: 33629112
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Peripheral lymphocyte count defines the clinical phenotypes and prognosis in patients with anti-MDA5-positive dermatomyositis.
    Jin Q; Fu L; Yang H; Chen X; Lin S; Huang Z; Gao B; Tian X; Jiang W; Shu X; Lu X; Wang G; Peng Q
    J Intern Med; 2023 Apr; 293(4):494-507. PubMed ID: 36682032
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Efficacy of plasma exchange in patients with anti-MDA5 rapidly progressive interstitial lung disease.
    Bay P; de Chambrun MP; Rothstein V; Mahevas M; De Prost N; Roux A; Zuber B; Biet DI; Hervier B; Tazi A; Mouthon L; Mekinian A; Deligny C; Borie R; Meurice JC; Meyer A; Priou P; Savale L; De Saint Martin L; Gallay L; Cottin V; Blanchard E; Brillet PY; Khafagy P; Benveniste O; Nunes H; Allenbach Y; Uzunhan Y
    J Autoimmun; 2022 Dec; 133():102941. PubMed ID: 36323067
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Disease characteristics and clinical outcomes of adults and children with anti-MDA-5 antibody-associated myositis: a prospective observational bicentric study.
    Dunga SK; Kavadichanda C; Gupta L; Naveen R; Agarwal V; Negi VS
    Rheumatol Int; 2022 Jul; 42(7):1155-1165. PubMed ID: 34050793
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Predictive factors of rapidly progressive-interstitial lung disease in patients with clinically amyopathic dermatomyositis.
    Xu Y; Yang CS; Li YJ; Liu XD; Wang JN; Zhao Q; Xiao WG; Yang PT
    Clin Rheumatol; 2016 Jan; 35(1):113-6. PubMed ID: 26660480
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Ultra-low dose rituximab as add-on therapy in anti-MDA5-positive patients with polymyositis /dermatomyositis associated ILD.
    Mao MM; Xia S; Guo BP; Qian WP; Zheng ZX; Peng XM; Chen RC; Luo Q; Han Q
    Respir Med; 2020 Oct; 172():105983. PubMed ID: 33032789
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Evaluation of usefulness in surfactant protein D as a predictor of mortality in myositis-associated interstitial lung disease.
    Kaieda S; Gono T; Masui K; Nishina N; Sato S; Kuwana M;
    PLoS One; 2020; 15(6):e0234523. PubMed ID: 32525903
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis.
    Wu W; Guo L; Fu Y; Wang K; Zhang D; Xu W; Chen Z; Ye S
    Clin Rev Allergy Immunol; 2021 Apr; 60(2):293-304. PubMed ID: 33405101
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Tumor markers are associated with rapidly progressive interstitial lung disease in adult-dermatomyositis.
    Wang Q; Gao C; Zhang C; Yao M; Liang W; Sun W; Zheng Z
    Clin Rheumatol; 2022 Jun; 41(6):1731-1739. PubMed ID: 35138465
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Clinical manifestations and outcome of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody positive patients with interstitial lung disease.
    Feng L; Wang H; Zhao Y; Zhao T; Zhang J; Huang F; Zhu J
    Clin Exp Rheumatol; 2022 Jan; 40(1):97-103. PubMed ID: 33635220
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Serum YKL-40 level is associated with severity of interstitial lung disease and poor prognosis in dermatomyositis with anti-MDA5 antibody.
    Jiang L; Wang Y; Peng Q; Shu X; Wang G; Wu X
    Clin Rheumatol; 2019 Jun; 38(6):1655-1663. PubMed ID: 30739212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.